MCID: PRX010
MIFTS: 28

Paroxysmal Ventricular Fibrillation

Categories: Rare diseases, Genetic diseases

Aliases & Classifications for Paroxysmal Ventricular Fibrillation

MalaCards integrated aliases for Paroxysmal Ventricular Fibrillation:

Name: Paroxysmal Ventricular Fibrillation 53
Paroxysmal Familial Ventricular Fibrillation 53 29 6 73
Ventricular Fibrillation, Idiopathic 53 55 6
Ventricular Fibrillation, Paroxysmal Familial 53
Idiopathic Ventricular Fibrillation 53
Ivf 53

Classifications:



External Ids:

UMLS 73 C0340493

Summaries for Paroxysmal Ventricular Fibrillation

MalaCards based summary : Paroxysmal Ventricular Fibrillation, also known as paroxysmal familial ventricular fibrillation, is related to idiopathic ventricular fibrillation, non brugada type and ventricular fibrillation, paroxysmal familial, 1. An important gene associated with Paroxysmal Ventricular Fibrillation is SCN5A (Sodium Voltage-Gated Channel Alpha Subunit 5). The drugs Spironolactone and Furosemide have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and kidney.

Related Diseases for Paroxysmal Ventricular Fibrillation

Graphical network of the top 20 diseases related to Paroxysmal Ventricular Fibrillation:



Diseases related to Paroxysmal Ventricular Fibrillation

Symptoms & Phenotypes for Paroxysmal Ventricular Fibrillation

Drugs & Therapeutics for Paroxysmal Ventricular Fibrillation

Drugs for Paroxysmal Ventricular Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 273)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Spironolactone Approved Phase 4,Phase 3 1952-01-7, 52-01-7 5833
2
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
3
Captopril Approved Phase 4 62571-86-2 44093
4
Ramipril Approved Phase 4 87333-19-5 5362129
5
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
6
Eplerenone Approved Phase 4,Phase 3 107724-20-9 150310 443872
7
Enalaprilat Approved Phase 4 76420-72-9 6917719
8
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
9
Dobutamine Approved Phase 4 34368-04-2 36811
10
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
11
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
12
Bisoprolol Approved Phase 4,Phase 3 66722-44-9 2405
13
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
14
Nitric Oxide Approved Phase 4 10102-43-9 145068 160954
15
Metoprolol Approved, Investigational Phase 4,Phase 2 37350-58-6, 51384-51-1 4171
16
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
17
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
18
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
19
Ticagrelor Approved Phase 4 274693-27-5 9871419
20
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
21
Nitroprusside Approved, Investigational Phase 4 15078-28-1 11963622
22
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 137-58-6 3676
23
Clopidogrel Approved Phase 4,Phase 3,Not Applicable 120202-66-6, 113665-84-2 60606
24
Sotalol Approved Phase 4,Phase 3 959-24-0, 3930-20-9 5253
25
Amiodarone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1951-25-3 2157
26
Tenecteplase Approved Phase 4,Phase 3 191588-94-0
27
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
28
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
29
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
30
Esmolol Approved Phase 4 103598-03-4, 81147-92-4 59768
31
Empagliflozin Approved Phase 4 864070-44-0
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-30-3 6037
33 Kava Approved, Investigational, Nutraceutical Phase 4,Not Applicable 9000-38-8
34
Candesartan Experimental Phase 4 139481-59-7 2541
35 calcium heparin Phase 4,Phase 3
36 diuretics Phase 4,Phase 3
37
protease inhibitors Phase 4,Phase 3,Not Applicable
38 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
39 Micronutrients Phase 4
40 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Not Applicable
41 Mineralocorticoid Receptor Antagonists Phase 4,Phase 3
42 Mineralocorticoids Phase 4,Phase 3
43 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
44 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2,Not Applicable
45 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
46 Natriuretic Agents Phase 4,Phase 3,Not Applicable
47 Sodium Potassium Chloride Symporter Inhibitors Phase 4
48 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
49 HIV Protease Inhibitors Phase 4,Phase 3,Not Applicable
50 Nitric Oxide Donors Phase 4

Interventional clinical trials:

(show top 50) (show all 311)
# Name Status NCT ID Phase Drugs
1 Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
2 Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure Reduced Ejection Fraction and Acute Decompensation With Low Cardiac Output (PRIORITY-ADHF Study) Unknown status NCT02767024 Phase 4 Sodium nitroprusside;Dobutamine;Furosemide
3 Magnesium to Reduce Implantable Cardioverter Defibrillator (ICD) Shocks and Improve Patient's Quality of Life. Unknown status NCT00282620 Phase 4 Magnesium L-lactate
4 Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients Unknown status NCT02200822 Phase 4 beta blockers;RAAS blockers
5 ADVANCE-D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy Completed NCT00147277 Phase 4
6 The Use of Dual Chamber ICD With Special Programmed Features to Lower the Risk of Inappropriate Shock Completed NCT00787800 Phase 4
7 VERRARI - "Are Ventricular Arrhythmic Episodes Reduced by Rate Response in ICDs?" Completed NCT00180427 Phase 4
8 Atorvastatin For The Reduction Of Ventricular Arrhythmias Completed NCT00457340 Phase 4 Atorvastatin 80mg
9 Remote Follow-up of Patients Receiving Implantable Cardioverter Defibrillator for Prophylactic Therapy Completed NCT00401466 Phase 4
10 ADVANCE CRT - D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy Completed NCT00147290 Phase 4
11 Trop-Shock DFT-testing Versus None Completed NCT01230086 Phase 4
12 Trial of Different Hypothermia Temperatures in Patients Recovered From Out-of-hospital Cardiac Arrest Completed NCT01155622 Phase 4
13 Transthoracic Incremental Monophasic Versus Biphasic by Emergency Responders (TIMBER) Completed NCT00101881 Phase 4
14 Influence of Home Monitoring on the Clinical Status of Heart Failure Patients With an Impaired Left Ventricular Function Completed NCT00538356 Phase 4
15 Acute Chest Pain Treatment and Evaluation (ACTION) Study Completed NCT00434564 Phase 4
16 RIGHT: Rhythm ID Going Head-to-Head Trial Completed NCT00148954 Phase 4
17 SMS: Substrate Modification Study in Patients Getting an Implantable Cardioverter Defibrillator (ICD) Completed NCT00170287 Phase 4
18 ASSURE Study - Arrhythmia Single Shock DFT Versus ULV: Risk Reduction Evaluation With ICD Implantations Completed NCT00231426 Phase 4
19 Clinical and Economical Interest of Endovascular Cooling in the Management of Cardiac Arrest (ICEREA Study) Completed NCT00392639 Phase 4
20 Fast VT Episodes Are Terminated by ATP One Shot Completed NCT00617578 Phase 4
21 Efficacy of Different Perioperative Statin Regimens on the Protection Against Post Coronary Artery Bypass Grafting Major Adverse Cardio-cerebral Events Completed NCT02706860 Phase 4 Atorvastatin
22 REFLEx Study (ENDOTAK RELIANCE G Evaluation of Handling and Electrical Performance Completed NCT00146822 Phase 4
23 'Effect of CRT on Defibrillation Threshold Estimates' Study Completed NCT00626093 Phase 4
24 TRUST: Lumos-T Safely RedUceS RouTine Office Device Follow-up Completed NCT00336284 Phase 4
25 Reduce Ventricular Pacing in Dual Chamber Implantable Cardioverter Defibrillators Using AutoIntrinsic Conduction Search Study Completed NCT00187239 Phase 4
26 Study to Verify Proper Detection of Supraventricular Tachyarrhythmia With Single-Lead Dual-Chamber Implantable Cardioverter-Defibrillators (ADRIA) Completed NCT00324662 Phase 4
27 Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction Completed NCT01176968 Phase 4 Eplerenone;Placebo
28 Temperature Control in Central Fever in the Neuro-ICU Completed NCT00751634 Phase 4
29 Survival of Patients With Primary Prophylactic ICD Indication Completed NCT00619593 Phase 4
30 Carvedilol Post-intervention Long-term Administration in Large-scale Trial Completed NCT01155635 Phase 4 Carvedilol;No Carvedilol
31 Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias Recruiting NCT02303639 Phase 4 Antiarrhythmic drug therapy
32 STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction Recruiting NCT02777580 Phase 4 Tenecteplase;Clopidogrel
33 Albumin in Cardiac Surgery Recruiting NCT02560519 Phase 4 Albumin solution;Ringers acetate solution
34 Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145) Recruiting NCT03346057 Phase 4 Sugammadex 2 mg/kg;Sugammadex 4 mg/kg;Sugammadex 16 mg/kg;Neostigmine + Glycopyrrolate
35 Esmolol in Cardiac Surgery Recruiting NCT00959569 Phase 4 Esmolol;Placebo
36 Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146) Recruiting NCT03346070 Phase 4 Sugammadex 2 mg/kg ABW;Sugammadex 2 mg/kg IBW;Sugammadex 4 mg/kg ABW;Sugammadex 4 mg/kg IBW;Neostigmine + Glycopyrrolate
37 Lidocaine vs Ketorolac for Management of Renal Colic in the Emergency Department Recruiting NCT03137498 Phase 4 Lidocaine;Ketorolac
38 To Determine Optimal Time for Delivering Electrical Shocks to Cardiac Arrest Patients Not yet recruiting NCT01665755 Phase 4
39 Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients Not yet recruiting NCT03271879 Phase 4 Empagliflozin at a dose of 10 mg/day
40 Effect of Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Right Ventricular Pacing Suspended NCT01868880 Phase 4 Ivabradine plus beta-blocker (bisoprolol);betablocker titration
41 High Low Biphasic Energy Defibrillation (HiLoBED) Unknown status NCT00429611 Phase 3
42 Impact of Hyperoxia During Cardiopulmonary Unknown status NCT02819739 Phase 3 medical oxygen
43 BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease Unknown status NCT00123916 Phase 3 Benznidazole;Placebo
44 RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy Unknown status NCT00127582 Phase 3
45 Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia Completed NCT01401647 Phase 3 amiodarone;Lidocaine
46 Ranolazine Implantable Cardioverter-Defibrillator Trial Completed NCT01215253 Phase 3 Ranolazine
47 AED Use in Out-of-Hospital Cardiac Arrest: A New Algorithm Named "One Shock Per Minute" Completed NCT00139542 Phase 3
48 Fatty Acid Antiarrhythmia Trial (FAAT) Completed NCT00004559 Phase 3
49 Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Completed NCT00000518 Phase 3 imipramine;mexiletine;procainamide;quinidine;sotalol
50 Safety and Effectiveness of Cardiac Resynchronization Therapy With Defibrillation Completed NCT00387803 Phase 2, Phase 3

Search NIH Clinical Center for Paroxysmal Ventricular Fibrillation

Genetic Tests for Paroxysmal Ventricular Fibrillation

Genetic tests related to Paroxysmal Ventricular Fibrillation:

# Genetic test Affiliating Genes
1 Paroxysmal Familial Ventricular Fibrillation 29

Anatomical Context for Paroxysmal Ventricular Fibrillation

MalaCards organs/tissues related to Paroxysmal Ventricular Fibrillation:

41
Heart, Testes, Kidney, Brain, Bone, Skin

Publications for Paroxysmal Ventricular Fibrillation

Articles related to Paroxysmal Ventricular Fibrillation:

(show all 12)
# Title Authors Year
1
Paroxysmal ventricular fibrillation--a case report. ( 7118139 )
1982
2
Paroxysmal ventricular fibrillation in children. Long-term follow-up of three cases treated with beta-blocking agents. ( 920265 )
1977
3
Quinidine syncope. Paroxysmal ventricular fibrillation treated with lidocaine. ( 1059946 )
1975
4
Familial Q-T prolongation syndrome. Convulsive seizures and paroxysmal ventricular fibrillation. ( 4834545 )
1974
5
Effect of propranolol on paroxysmal ventricular fibrillation. ( 5956507 )
1966
6
Quinidine-induced paroxysmal ventricular fibrillation treated with propranolol. ( 5941503 )
1966
7
PAROXYSMAL VENTRICULAR FIBRILLATION WITH SPONTANEOUS REVERSION TO SINUS RHYTHM. ( 14242165 )
1965
8
QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS. ( 14197832 )
1964
9
PAROXYSMAL VENTRICULAR FIBRILLATION. ( 14180668 )
1964
10
Paroxysmal ventricular fibrillation in the absence of other disease. ( 13459129 )
1957
11
Paroxysmal ventricular fibrillation producing Adams-Stokes syndrome; report of a case on quinidine therapy with spontaneous recovery. ( 13231194 )
1954
12
Paroxysmal ventricular fibrillation producing Adams-Stokes syndrome; report of case with review of literature. ( 14952058 )
1952

Variations for Paroxysmal Ventricular Fibrillation

ClinVar genetic disease variations for Paroxysmal Ventricular Fibrillation:

6
(show top 50) (show all 178)
# Gene Variation Type Significance SNP ID Assembly Location
1 SCN5A NM_198056.2(SCN5A): c.3308C> A (p.Ser1103Tyr) single nucleotide variant risk factor rs7626962 GRCh37 Chromosome 3, 38620907: 38620907
2 SCN5A NM_198056.2(SCN5A): c.3308C> A (p.Ser1103Tyr) single nucleotide variant risk factor rs7626962 GRCh38 Chromosome 3, 38579416: 38579416
3 CACNB2 NM_000724.3(CACNB2): c.215C> T (p.Ala72Val) single nucleotide variant Uncertain significance rs200367454 GRCh37 Chromosome 10, 18787330: 18787330
4 CACNB2 NM_000724.3(CACNB2): c.215C> T (p.Ala72Val) single nucleotide variant Uncertain significance rs200367454 GRCh38 Chromosome 10, 18498401: 18498401
5 SCN5A NM_198056.2(SCN5A): c.1569T> A (p.Arg523=) single nucleotide variant Conflicting interpretations of pathogenicity rs41313693 GRCh37 Chromosome 3, 38645524: 38645524
6 SCN5A NM_198056.2(SCN5A): c.1569T> A (p.Arg523=) single nucleotide variant Conflicting interpretations of pathogenicity rs41313693 GRCh38 Chromosome 3, 38604033: 38604033
7 SCN5A NM_198056.2(SCN5A): c.6003C> T (p.Leu2001=) single nucleotide variant Conflicting interpretations of pathogenicity rs538707712 GRCh37 Chromosome 3, 38591860: 38591860
8 SCN5A NM_198056.2(SCN5A): c.6003C> T (p.Leu2001=) single nucleotide variant Conflicting interpretations of pathogenicity rs538707712 GRCh38 Chromosome 3, 38550369: 38550369
9 SCN5A NM_198056.2(SCN5A): c.4824C> T (p.Leu1608=) single nucleotide variant Conflicting interpretations of pathogenicity rs45437099 GRCh37 Chromosome 3, 38593039: 38593039
10 SCN5A NM_198056.2(SCN5A): c.4824C> T (p.Leu1608=) single nucleotide variant Conflicting interpretations of pathogenicity rs45437099 GRCh38 Chromosome 3, 38551548: 38551548
11 SCN5A NM_198056.2(SCN5A): c.1068T> C (p.Asp356=) single nucleotide variant Conflicting interpretations of pathogenicity rs41313703 GRCh37 Chromosome 3, 38648232: 38648232
12 SCN5A NM_198056.2(SCN5A): c.1068T> C (p.Asp356=) single nucleotide variant Conflicting interpretations of pathogenicity rs41313703 GRCh38 Chromosome 3, 38606741: 38606741
13 SCN5A NM_001099404.1(SCN5A): c.1598G> A (p.Arg533His) single nucleotide variant Uncertain significance rs146848219 GRCh37 Chromosome 3, 38645495: 38645495
14 SCN5A NM_001099404.1(SCN5A): c.1598G> A (p.Arg533His) single nucleotide variant Uncertain significance rs146848219 GRCh38 Chromosome 3, 38604004: 38604004
15 SCN5A NM_198056.2(SCN5A): c.4109A> G (p.Asp1370Gly) single nucleotide variant Uncertain significance rs775485359 GRCh37 Chromosome 3, 38601774: 38601774
16 SCN5A NM_198056.2(SCN5A): c.4109A> G (p.Asp1370Gly) single nucleotide variant Uncertain significance rs775485359 GRCh38 Chromosome 3, 38560283: 38560283
17 SCN5A NM_198056.2(SCN5A): c.2956C> T (p.Arg986Trp) single nucleotide variant Uncertain significance rs561547165 GRCh37 Chromosome 3, 38622694: 38622694
18 SCN5A NM_198056.2(SCN5A): c.2956C> T (p.Arg986Trp) single nucleotide variant Uncertain significance rs561547165 GRCh38 Chromosome 3, 38581203: 38581203
19 SCN5A NM_198056.2(SCN5A): c.787G> A (p.Val263Ile) single nucleotide variant Uncertain significance rs752824646 GRCh37 Chromosome 3, 38651372: 38651372
20 SCN5A NM_198056.2(SCN5A): c.787G> A (p.Val263Ile) single nucleotide variant Uncertain significance rs752824646 GRCh38 Chromosome 3, 38609881: 38609881
21 LMNA NM_170707.3(LMNA): c.80C> G (p.Thr27Ser) single nucleotide variant Uncertain significance rs863225270 GRCh37 Chromosome 1, 156084789: 156084789
22 LMNA NM_170707.3(LMNA): c.80C> G (p.Thr27Ser) single nucleotide variant Uncertain significance rs863225270 GRCh38 Chromosome 1, 156114998: 156114998
23 DSP NM_004415.3(DSP): c.7186T> A (p.Tyr2396Asn) single nucleotide variant Uncertain significance rs863225268 GRCh37 Chromosome 6, 7584681: 7584681
24 DSP NM_004415.3(DSP): c.7186T> A (p.Tyr2396Asn) single nucleotide variant Uncertain significance rs863225268 GRCh38 Chromosome 6, 7584448: 7584448
25 SCN5A NM_001099404.1(SCN5A): c.4267G> A (p.Asp1423Asn) single nucleotide variant Uncertain significance rs746291609 GRCh37 Chromosome 3, 38598754: 38598754
26 SCN5A NM_001099404.1(SCN5A): c.4267G> A (p.Asp1423Asn) single nucleotide variant Uncertain significance rs746291609 GRCh38 Chromosome 3, 38557263: 38557263
27 SCN5A NM_198056.2(SCN5A): c.5607C> T (p.Asp1869=) single nucleotide variant Conflicting interpretations of pathogenicity rs560476223 GRCh38 Chromosome 3, 38550765: 38550765
28 SCN5A NM_198056.2(SCN5A): c.5607C> T (p.Asp1869=) single nucleotide variant Conflicting interpretations of pathogenicity rs560476223 GRCh37 Chromosome 3, 38592256: 38592256
29 SCN5A NM_198056.2(SCN5A): c.5454C> T (p.Ala1818=) single nucleotide variant Conflicting interpretations of pathogenicity rs370114378 GRCh38 Chromosome 3, 38550918: 38550918
30 SCN5A NM_198056.2(SCN5A): c.5454C> T (p.Ala1818=) single nucleotide variant Conflicting interpretations of pathogenicity rs370114378 GRCh37 Chromosome 3, 38592409: 38592409
31 SCN5A NM_198056.2(SCN5A): c.3542T> C (p.Val1181Ala) single nucleotide variant Uncertain significance rs376965389 GRCh37 Chromosome 3, 38616912: 38616912
32 SCN5A NM_198056.2(SCN5A): c.3542T> C (p.Val1181Ala) single nucleotide variant Uncertain significance rs376965389 GRCh38 Chromosome 3, 38575421: 38575421
33 SCN5A NM_198056.2(SCN5A) insertion Likely benign rs45592631 GRCh38 Chromosome 3, 38548175: 38548176
34 SCN5A NM_198056.2(SCN5A) insertion Likely benign rs45592631 GRCh37 Chromosome 3, 38589666: 38589667
35 SCN5A NM_198056.2(SCN5A): c.*1701G> T single nucleotide variant Uncertain significance rs886058441 GRCh38 Chromosome 3, 38548620: 38548620
36 SCN5A NM_198056.2(SCN5A): c.*1701G> T single nucleotide variant Uncertain significance rs886058441 GRCh37 Chromosome 3, 38590111: 38590111
37 SCN5A NM_198056.2(SCN5A): c.*1602G> T single nucleotide variant Uncertain significance rs886058444 GRCh38 Chromosome 3, 38548719: 38548719
38 SCN5A NM_198056.2(SCN5A): c.*1602G> T single nucleotide variant Uncertain significance rs886058444 GRCh37 Chromosome 3, 38590210: 38590210
39 SCN5A NM_198056.2(SCN5A): c.*1537T> C single nucleotide variant Likely benign rs41315485 GRCh38 Chromosome 3, 38548784: 38548784
40 SCN5A NM_198056.2(SCN5A): c.*1537T> C single nucleotide variant Likely benign rs41315485 GRCh37 Chromosome 3, 38590275: 38590275
41 SCN5A NM_198056.2(SCN5A): c.*1165C> T single nucleotide variant Likely benign rs41313017 GRCh38 Chromosome 3, 38549156: 38549156
42 SCN5A NM_198056.2(SCN5A): c.*1165C> T single nucleotide variant Likely benign rs41313017 GRCh37 Chromosome 3, 38590647: 38590647
43 SCN5A NM_198056.2(SCN5A): c.*1164G> T single nucleotide variant Uncertain significance rs41315489 GRCh38 Chromosome 3, 38549157: 38549157
44 SCN5A NM_198056.2(SCN5A): c.*1164G> T single nucleotide variant Uncertain significance rs41315489 GRCh37 Chromosome 3, 38590648: 38590648
45 SCN5A NM_198056.2(SCN5A): c.*980C> A single nucleotide variant Uncertain significance rs886058449 GRCh38 Chromosome 3, 38549341: 38549341
46 SCN5A NM_198056.2(SCN5A): c.*980C> A single nucleotide variant Uncertain significance rs886058449 GRCh37 Chromosome 3, 38590832: 38590832
47 SCN5A NM_198056.2(SCN5A): c.*963C> T single nucleotide variant Likely benign rs4073796 GRCh38 Chromosome 3, 38549358: 38549358
48 SCN5A NM_198056.2(SCN5A): c.*963C> T single nucleotide variant Likely benign rs4073796 GRCh37 Chromosome 3, 38590849: 38590849
49 SCN5A NM_198056.2(SCN5A): c.*889C> A single nucleotide variant Uncertain significance rs546849670 GRCh38 Chromosome 3, 38549432: 38549432
50 SCN5A NM_198056.2(SCN5A): c.*889C> A single nucleotide variant Uncertain significance rs546849670 GRCh37 Chromosome 3, 38590923: 38590923

Expression for Paroxysmal Ventricular Fibrillation

Search GEO for disease gene expression data for Paroxysmal Ventricular Fibrillation.

Pathways for Paroxysmal Ventricular Fibrillation

GO Terms for Paroxysmal Ventricular Fibrillation

Sources for Paroxysmal Ventricular Fibrillation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....